Linezolid induced refractory lactic acidosis causing atrial fibrillation – A case report of serious adverse event
Abstract
Linezolid has been approved for treatment of MDR and XDR TB by WHO. It is one of the most effective drugs for treating drug-resistant tuberculosis (DR-TB), but it carries a considerable risk of toxicity and is poorly tolerated because of its side effects of peripheral neuropathy, anemia/thrombocytopenia and optic neuritis etc. Linezolid may also induce lactic acidosis. The incidence of lactic acidosis is relatively low but it is a serious adverse drug reaction that can result in multi-organ failure and death. We report a case of linezolid induced refractory lactic acidosis causing atrial fibrillation in a 20-year old female receiving “all oral longer regimen” for MDR tuberculosis.
Downloads
References
2. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect. 2009;59(Suppl1):S59–S74.
3. Waldrep TW, Skiest DJ. Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy. 2002;22(1):109–112.
4. Rho JP, Sia IG, Crum BA, Dekutoski MB, Trousdale RT. Linezolid-associated peripheral neuropathy. Mayo Clin Proc. 2004;79(7):927–930.
5. Karuppannasamy D, Raghuram A, Sundar D. Linezolid-induced optic neuropathy. Indian J Ophthalmol. 2014;62(4):497–500.
6. Im JH, Baek JH, Kwon HY, Lee JS. Incidence and risk factors of linezolid-induced lactic acidosis. Int J Infect Dis. 2015; 31:47–52.
7. Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med 2003;348:86–7.
8. Yiyang Mao, BS, Danping Dai, BS, Haiying Jin, MS,∗ and Yangyang Wang, BS
Monitoring Editor: Jianxun Ding.The risk factors of linezolid-induced lactic acidosis :A
case report and review. Medicine (Baltimore). 2018 Sep; 97(36): e12114.
9 Alessandro Santini , Dario Ronchi , Manuela Garbellini , Daniela Piga , Alessandro Protti .Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes. Expert Opin Drug Saf. 2017 Jul;16(7):833-843.
10 Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012; 367:1508–18.
11 Rose PC, Hallbauer UM, Seddon JA, Hesseling AC, Schaaf HS. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis. 2012;16: 1588–93.
12 Habib Ur Rehman. Linezolid-induced Lactic Acidosis. Eur J Gen Med 2016;13(2):149-151.
13 An S. De Vriese, Rudy Van Coster, Joél Smet, et.al. Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis. Clinical Infectious Diseases 2006; 42 (8):1111–1117.
14 Allessie MA, Boyden PA, Camm AJ, Kleber AG, Lab MJ, Legato MJ, Rosen MR, Schwartz PJ, Spooner PM, Van Wagoner DR, Waldo AL. Pathophysiology and prevention of atrial fibrillation. Circulation 2001; 103 (5), 769–777.
15 Luft FC. Lactic acidosis update for critical care clinicians. Journal of American Society of Nephrology 2001; 12 (Suppl 17), S15–19.
16 Karmazyn M. Antiarrhythmic effects of Na-H exchange inhibition. Drug Development Research 2002; 55 (1), 22–28.
This work is licensed under a Creative Commons Attribution 4.0 International License.
